Cargando…
Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
The stimulation of mineralocorticoid receptors is linked to the development of hypertension and cardiovascular or renal damage in patients with diabetes, and the blockade of these receptors may be an effective treatment option. This open-label study with a 12-week treatment period assessed the antih...
Autores principales: | Itoh, Hiroshi, Ito, Sadayoshi, Rakugi, Hiromi, Okuda, Yasuyuki, Nishioka, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075891/ https://www.ncbi.nlm.nih.gov/pubmed/31239535 http://dx.doi.org/10.1038/s41440-019-0270-2 |
Ejemplares similares
-
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020) -
Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
por: Kario, Kazuomi, et al.
Publicado: (2021) -
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2019) -
Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019) -
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)